Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma Colby S. ShemeshPriya AgarwalDan Lu Original Article Open access 28 March 2020 Pages: 831 - 842
Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer Tetsuaki ShojiEiki KikuchiSatoshi Konno Original Article 30 March 2020 Pages: 843 - 853
Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors Akihito KawazoeYasutoshi KubokiTakayuki Yoshino Original Article Open access 31 March 2020 Pages: 855 - 862
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer Igal KushnirRanjeeta MallickNeil M. Reaume Original Article 02 April 2020 Pages: 863 - 868
Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model Shuhei SakaiShinji KobuchiToshiyuki Sakaeda Original Article 02 April 2020 Pages: 869 - 880
Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis Lin YangHui WuRui-xiang Xie Original Article 03 April 2020 Pages: 881 - 897
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects Ken OgasawaraChristine XuGopal Krishna Original Article 04 April 2020 Pages: 899 - 906
A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors Yiqian LiuLianke LiuYongqian Shu Original Article Open access 07 April 2020 Pages: 907 - 915
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer Sanne C. F. A. HuijbertsRobin M. J. M. van GeelJan H. M. Schellens Original Article 09 April 2020 Pages: 917 - 930
Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study L. H. MammatasA. S. ZandvlietH. M. W. Verheul Original Article Open access 09 April 2020 Pages: 931 - 940
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine Hiroaki SoyamaMorikazu MiyamotoMasashi Takano Original Article 11 April 2020 Pages: 941 - 947
Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy Xin WeiJiabin NianMin Zeng Original Article 11 April 2020 Pages: 949 - 957
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation Bin FanDavid DaiHua Yang Original Article 15 April 2020 Pages: 959 - 968
The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study Jinsong SuBaiyun DaiJunmin Song Original Article 20 April 2020 Pages: 969 - 978
Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors Geraldine O.’Sullivan CoyneLihua WangJames H. Doroshow Original Article Open access 20 April 2020 Pages: 979 - 993
A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects Ken OgasawaraBradley VinceGopal Krishna Original Article 22 April 2020 Pages: 995 - 1001
Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib Priya S. ShankarappaCody J. PeerKatherine E. Warren Short Communication 18 April 2020 Pages: 1003 - 1007
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer Hani M. BabikerMohammed MilhemThai Ho Correction 25 March 2020 Pages: 1009 - 1010